Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Salk Institute announces second Helmsley-Salk Fellow

December 2, 2014 – 5:00 pm | Edit Post

LA JOLLA–The Salk Institute is pleased to announce its second appointment in the new Salk Fellows Program. The program, which brings scientists from across disciplines to tackle big problems in biology, welcomes scientist Jesse Dixon as a Helmsley-Salk Fellow.

Sienna Labs Obtains Fifth Patent Relating To Use Of Plasmonic Nanoparticles In Treatment Of Sebaceous Glands And Hair

December 2, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 /PRNewswire/ –Sienna Labs announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,895,071 covering, among other aspects, methods of using the company’s plasmonic nanoparticle platform for localizing thermal damage to sebaceous glands and hair, a key mechanism…

Regen BioPharma Scheduled To Make Presentation At American Society of Hematology’s 56th Annual Meeting In San Francisco December 6th – 9th

December 2, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – December 01, 2014) – Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled “NR2F6 (EAR-2) Is a Novel Leukemia…

Organovo Collaborates With Yale University School Of Medicine Team To Develop 3-D Organ Tissues For Surgical Transplantation Research

December 2, 2014 – 5:00 pm | Edit Post

SAN DIEGO, NEW HAVEN, Conn. and SPRINGFIELD, Va., Dec. 3, 2014 /PRNewswire/ –Organovo Holdings, Inc.(NYSE MKT: ONVO) (“Organovo”), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, and …

Illumina And Sequenom Inc. Pool Noninvasive Prenatal Testing Intellectual Property And End Outstanding Patent Disputes

December 2, 2014 – 5:00 pm | Edit Post

Illumina and Sequenom Pool Noninvasive Prenatal Testing Intellectual Property and End Outstanding Patent DisputesSAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) and Sequenom, Inc. (NASDAQ: SQNM) today announced they have agreed to settle all pending infringement claims and other disputes between Sequenom and Verinata Health, Inc. The parties will pool…

Regen BioPharma Scheduled To Make Presentation At American Society of Hematology’s 56th Annual Meeting In San Francisco December 6th – 9th

December 2, 2014 – 5:00 pm | Edit Post

SAN DIEGO, CA–(Marketwired – December 01, 2014) – Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled “NR2F6 (EAR-2) Is a Novel Leukemia…

Sienna Labs Obtains Fifth Patent Relating To Use Of Plasmonic Nanoparticles In Treatment Of Sebaceous Glands And Hair

December 2, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 /PRNewswire/ –Sienna Labs announced today that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,895,071 covering, among other aspects, methods of using the company’s plasmonic nanoparticle platform for localizing thermal damage to sebaceous glands and hair, a key mechanism…

Illumina, Inc. Moving Forward With San Diego Expansion, 300 New Jobs

December 2, 2014 – 5:00 pm | Edit Post

Salk Institute announces second Helmsley-Salk Fellow

December 2, 2014 – 5:00 pm | Edit Post

LA JOLLA–The Salk Institute is pleased to announce its second appointment in the new Salk Fellows Program. The program, which brings scientists from across disciplines to tackle big problems in biology, welcomes scientist Jesse Dixon as a Helmsley-Salk Fellow.

Lpath, Inc. Completes Enrollment In Its Phase 2 Clinical Trial Of iSONEP For Wet Age-Related Macular Degeneration

December 2, 2014 – 5:00 pm | Edit Post

SAN DIEGO, Dec. 2, 2014 /PRNewswire/ –Lpath, Inc.(NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, announced that in consultation with Pfizer Inc., Lpath has completed enrollment of its clinical trial evaluating iSONEP in patients with wet age-related macular degeneration (wet AMD…